Trial Profile
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- Acronyms Alliance A091404
- 22 Jul 2022 Results published in the Journal of Clinical Oncology
- 06 Oct 2021 Planned End Date changed from 5 Jul 2021 to 5 Jul 2022.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology